Skip to main content
. Author manuscript; available in PMC: 2009 Aug 12.
Published in final edited form as: Nature. 2009 Feb 12;457(7231):910–914. doi: 10.1038/nature07762

Figure 2. Metabolomic alterations of prostate cancer progression.

Figure 2

a, Heat map showing 87 differential metabolites in PCA relative to benign samples (Wilcoxon P ≤ 0.05). Localized PCA samples are grouped as i., low grade (Gleason<6) and ii., high grade (Gleason>=7). Metastatic samples are grouped by the site of tissue procurement namely iii., soft tissue, iv., rib/diaphragm or v., liver. b, Benign-based z-score plot of named metabolites from a. Each point represents one metabolite in one sample, colored by tissue type (jade=benign, yellow=PCA). c, As in b except for the comparison between Mets (red) and PCA (yellow), with data represented relative to the mean of the PCA samples. For clarity, the plots in b and c have been truncated at 15 standard deviations above the mean of the benign and PCA samples, respectively.